Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Esperion Therapeutics, Inc.
< Previous
1
2
3
Next >
Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk
December 02, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
November 26, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
November 21, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
November 18, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 08, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
November 07, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in Upcoming Jefferies London Healthcare Conference
November 04, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
October 31, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Report Third Quarter 2024 Financial Results on November 7
October 24, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
October 02, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
September 25, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
September 05, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
September 03, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
August 26, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
August 12, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 07, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Report Second Quarter 2024 Financial Results on August 12
July 25, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in Upcoming BTIG Biotech Conference
July 24, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
July 16, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
June 28, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in Upcoming June Investor Conferences
May 23, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
May 22, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
May 20, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
May 14, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 10, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Reports First Quarter 2024 Financial Results
May 07, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in Upcoming May Investor Conferences
April 29, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Report First Quarter 2024 Financial Results on May 7
April 23, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
April 07, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
April 01, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.